PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results

D-PLEX₁₀₀ NDA Under FDA Priority Review with PDUFA Goal Date of November 28, 2026; U.S. Commercial Launch Preparations OngoingExpanding D-PLEX₁₀₀ Globally: MAA Submitted and Validated by the EMA and European Commercialization Rights to D-PLEX₁₀₀ Regained“PolyPid 2030” Growth Strategy Unveiled, Intr…